Lessons from a Rare Familial Dementia: Amyloid and Beyond

Journal Title: Journal of Parkinson’s Disease and Alzheimer’s Disease - Year 2015, Vol 2, Issue 1

Abstract

Here we review the similarities between a rare inherited disorder, familial British dementia (FBD), and the most common of all late-life neurological conditions, Alzheimer’s diseases (AD). We describe the symptoms, pathology and genetics of FBD, the biology of the BRI2 protein and mouse models of FBD and familial Danish dementia. In particular, we focus on the evolving recognition of the importance of protein oligomers and aberrant processing of the amyloid β-protein precursor (APP) - themes that are common to both FBD and AD. The initial discovery that FBD is phenotypically similar to AD, but associated with the deposition of an amyloid peptide (ABri) distinct from the amyloid β-protein (Aβ) led many to assume that amyloid production alone is sufficient to initiate disease and that ABri is the molecular equivalent of Aβ. Parallel with work on Aβ, studies of ABri producing animal models and in vitro ABri toxicity experiments caused a revision of the amyloid hypothesis and a focus on soluble oligomers of Aβ and ABri. Contemporaneous other studies suggested that loss of the ABri precursor protein (BRI2) may underlie the cognitive deficits in FBD. In this regard it is important to note that BRI2 has been shown to interact with and regulate the processing of APP, and that mutant BRI2 leads to altered cleavage of APP. A synthesis of these results suggests that a “two-hit mechanism” better explains FBD than earlier toxic gain of function and toxic loss of function models. The lessons learned from the study of FBD imply that the molecular pathology of AD is also likely to involve both aberrant aggregation (in AD, Aβ) and altered APP processing. With regard to FBD, we propose that the C-terminal 11 amino acid of FBD-BRI2 interfere with both the normal function of BRI2 and promotes the production of cystine cross-linked toxic ABri oligomers. In this scenario, loss of BRI2 function leads to altered APP processing in as yet underappreciated ways. Given the similarities between FBD and AD it seems likely that study of the structure of ABri oligomers and FBD-induced changes in APP metabolites will further our understanding of AD.

Authors and Affiliations

Dominic M. Walsh

Keywords

Related Articles

Classification of Parkinson’s Disease Using Data Mining Techniques

Parkinson’s disease is a human disease caused by tolerant disorder of the nervous system that affects movement. It grows slowly, occasionally initiated with a scarcely visible tremor in just one hand. But while a tremor...

Dihydrolipoic Acid Conjugated Carbon Dots Accelerate Human Insulin Fibrillation

Protein fibrillation is believed to play an important role in the pathology and development of several human diseases, such as Alzheimer’s disease, Parkinson’s disease, and type 2 diabetes. Carbon dots (CDs), as a new ty...

Two Patients with Migraine and Parkinsonism: A Possible Relationship?

Migraine is linked to an increased occurrence of neurological movement disorders including Parkinsonism. We describe two women with chronic, severe migraine with aura who later in life developed Parkinsonism. In both cas...

A Possible Mechanism for the Propagation of Pathological Proteins in Parkinson’s Disease

Parkinson’s disease is a common neurodegenerative disorder which recently has come to be regarded as a prion-like foldopathy, the latter term implying that the intercellular trafficking of abnormally folded proteins tran...

Effects of Physical Exercise on Cognition in Persons with Subjective Cognitive Decline or Mild Cognitive Impairment: A Review

Alzheimer’s disease is the most common type of dementia that lacks a cure so prevention is an important aspect of care. Persons with subjective cognitive decline or mild cognitive impairment are more likely to be diagnos...

Download PDF file
  • EP ID EP207471
  • DOI 10.13188/2376-922X
  • Views 100
  • Downloads 0

How To Cite

Dominic M. Walsh (2015). Lessons from a Rare Familial Dementia: Amyloid and Beyond. Journal of Parkinson’s Disease and Alzheimer’s Disease, 2(1), 1-12. https://europub.co.uk/articles/-A-207471